Kit for detecting related immunophenotyping of B-cell acute lymphoblastic leukemia and application thereof

Abstract

The invention discloses a kit for detecting a related immunophenotyping of B-cell acute lymphoblastic leukemia and forms classification equipment of a related immunophenotyping of leukemia with a seven-color flow cytometry. The kit is configured with the following monoclonal antibody reagent combinations: CD58, CD10, CD34, CD123, CD38, CD19 and CD45, and fluorescein is respectively marked according to front and back sequences as follows: FITC (fluorescein isothiocyanate), PE (pulmonary embolism), PerCP-CY5,5, PE-CY7 (phycoerythrin-CY7), APC (adenomatous polyposis coli), APC-Cy7 and PacificBlue. With the adoption of the kit disclosed by the invention, whether the seven marks are normal or not can be simultaneously observed, and the sensitivity and the accuracy of the detection are increased; further, immunophenotyping information in morbidity can not be relied on, so that the range and capacity of the LAIP (leukemia associated immunophenotyping) analysis are expanded, the early-stage conditions of the analysis are simplified, and more chances are provided for clinical detection of MRD (minimal residual disease).

Description

technical field [0001] The invention belongs to a special kit in the process of confirming cell phenotypes, and in particular relates to a kit for detecting immunophenotypes related to acute B lymphocytic leukemia and its application. Background technique [0002] With the improvement of treatment strategies and the continuous emergence of new chemotherapy drugs, the remission rate and survival rate of acute lymphoblastic leukemia (ALL) have been greatly improved, but there are still some patients with poor prognosis and eventually die of relapse. Even with intensive chemotherapy or even hematopoietic stem cell transplantation after relapse, it is still difficult to save the patient's life, which has caused extremely heavy mental and economic burdens to society and families. Studies have proven that the level of minimal residual disease (MRD) after treatment is the root cause of relapse. [0003] Multi-parameter flow cytometry (flow cytometry, FCM) is one of the commonly ...

AI Technical Summary

Problems solved by technology

[0005] In order to improve the detection sensitivity, three-color FCM or four-color FCM often requires multiple sets of antibody combinations, each of which contains the same antibody, which increases the total number of antibodies on the one hand, thereby increasing the cost of the test and the financial burden on patients ; On the other hand, multiple groups of antibody combinations need to be detected separately in multiple tubes, which affects the multi-parameter analysis of the detection antibodies: when analyzing LAIP, sometimes it is necessary to set a gate for multiple markers to limit a group of cells, for example, in the first tube of antibody combination A population of suspicious LAIP-positive cells was found, phenotyped as CD45 + CD19 + CD10 + CD34 - , but the number of cells in this group is low (-4 ), it is often necessary to observe whether the expression of other antigens in this group of cells is abnormal to determine whether there is LAIP; but the four-color combination cannot detect antibodies other than the fourth one at the same time, which affects the accuracy of the detection; to observe this group of cells Whether there is abnormal expression of the fifth or other antigens of the cells, it cannot be done by using four-color FCM

Images